| Methods | n = 10 Allocation concealment: not described Baseline similarity: not described Blinding: unclear ("single‐blind", placebo used) Cointerventions: not described Withdrawals: none Losses to follow‐up: none |
|
| Participants | Inclusions: Risk factor: sepsis syndrome; PaO2 < 60 mmHg or intrapulmonary shunt > 20% or radiologic evidence of ARDS Exclusions: Major cardiac, pulmonary, renal, endocrine diseases |
|
| Interventions | IV dazoxiben, 100 mg every 4 hours for 72 hours, or placebo | |
| Outcomes | Mortality: RR 2.00 (95% CI 0.26 to 15.62) Adverse events leading to discontinuation of therapy: none |
|
| Notes | ||
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.